Online inquiry

IVTScrip™ mRNA-Anti-CD19, MEDI-551(Cap 1, N1-Methylpseudo-UTP, 120 nt-poly(A))   (CAT#: GTTS-WQ11344MR)

This product GTTS-WQ11344MR is a type of mRNA having 120 nt poly(A) tail and modified with Cap 1 & N1-Methylpseudo-UTP. It ecodes the monoclonal antibody that targets CD19 gene. The antibody can be applied in Chronic lymphocytic leukemia (CLL), Neuromyelitis optica (NMO) research.
Specifications
Product type mRNA
Modified bases N1-Methylpseudo-UTP
5' Cap Cap 1
Species Humanized
RefSeq NM_001178098.2
Applications Gene therapy research
Format Powder
Quantity 100 µg
Purification oligo-dT affinity purification
Target Gene
Gene ID 930
UniProt ID P15391
Download
Download resources about mRNA therapeutics development to boost your research.
CUSTOMER REVIEWS and Q&As

There are currently no Customer reviews or questions for IVTScrip™ mRNA-Anti-CD19, MEDI-551(Cap 1, N1-Methylpseudo-UTP, 120 nt-poly(A)) (GTTS-WQ11344MR). Click the button above to contact us or submit your feedback about this product.

See other products
CAT Product Name Product Type CDs
GTTS-WQ15124MR IVTScrip™ mRNA-Anti-ERBB2, SYD985(Cap 0, Pseudo-UTP, 30 nt-poly(A)) mRNA SYD985
GTTS-WQ4057MR IVTScrip™ mRNA-Anti-IL36RN, BI 655130(Cap 0, N1-Methylpseudo-UTP, 30 nt-poly(A)) mRNA BI 655130
GTTS-WQ8050MR IVTScrip™ mRNA-Anti-F, H1H3592P3(Cap 1, 5-Methyl-CTP, 30 nt-poly(A)) mRNA H1H3592P3
GTTS-WQ9533MR IVTScrip™ mRNA-Anti-FOLH1, J-591(Cap 1, Pseudo-UTP, 30 nt-poly(A)) mRNA J-591
GTTS-WQ6871MR IVTScrip™ mRNA-Anti-KLKB1, DX-2930(Cap 0, 5-Methyl-CTP, 120 nt-poly(A)) mRNA DX-2930
GTTS-WQ9865MR IVTScrip™ mRNA-Anti-CD37, K7153A(Cap 0, 2-Thio-UTP, 30 nt-poly(A)) mRNA K7153A
GTTS-WQ2284MR IVTScrip™ mRNA-Anti-C5, ALXN1007(Cap 1, 2-Thio-UTP, 120 nt-poly(A)) mRNA ALXN1007
GTTS-WQ12021MR IVTScrip™ mRNA-Anti-ERBB2, MM-302(Cap 0, 5-Methoxy-UTP, 30 nt-poly(A)) mRNA MM-302
All products and services are For Research Use Only and CANNOT be used in the treatment or diagnosis of disease.
webinar

EABR Nanoparticles as a Platform Technology for Hybrid mRNA Vaccine Development

November 20th, 2024, 2 PM–3 PM EST

REGISTER NOW